Interstitial Lung Disease (ILD) Treatment Market to Reach USD 3.22 Bn by 2034

Vantage Market Research releases its latest comprehensive report on the ‘Interstitial Lung Disease (ILD) Treatment Market’ with a forecast period of 2025-2034. In 2023, the global interstitial lung disease treatment market size was USD 1.61 Billion, and is calculated at USD 1.71 billionin 2024. The interstitial lung disease treatment market is projected to reach USD 3.22 billion in 2034, and register a revenue CAGR of 6.5% over the forecast period (2025-2034).

Market Overview:

The global Interstitial Lung Disease (ILD) treatment market is registering steady revenue growth owing to factors such as rising prevalence rates of ILDs, particularly Idiopathic Pulmonary Fibrosis (IPF), often associated with aging populations and environmental risk factors. Increased awareness regarding ILDs and advances in high-resolution diagnostic tools such as CT scans are also contributing to market growth to a significant extent. These advances are prompting early detection rates and supporting demand for interstitial lung disease treatment options among an expanding patient pool. The availability of advanced therapies, notably antifibrotic drugs like nintedanib and pirfenidone, is transforming ILD management and expected to drive market growth over the forecast period.

Ongoing investments in pharmaceutical Research and Development (R&D) also plays a crucial role in market growth, with companies focusing on novel treatments for ILD, backed by government funding and fast-track regulatory approvals. Emerging markets in Asia Pacific and Latin America are seeing rising demand for ILD treatments, driven by expanding healthcare infrastructure and improved access to treatments. Strategic partnerships, mergers, and acquisitions among key players are accelerating innovation and expanding therapeutic options. Increased demand for interstitial lung disease treatments is also supported by rising healthcare investments and public awareness initiatives. Aging populations and age-related susceptibility to ILD, as well as occupational and environmental risk factors are contributing to incline in ILD prevalence. Moreover, pharmaceutical companies are prioritizing treatment development for adults over 50 years, who require long-term therapies and comprehensive management solutions.

Furthermore, diagnostic advancements in ILD, including chest X-rays and high-resolution CT scans, allow more precise imaging of lung structures and enable early intervention. Lung function tests and blood oxygen measurements support diagnosis and treatment monitoring, reducing the need for invasive biopsies. Anti-inflammatory and anti-fibrotic drugs, especially beneficial in sarcoidosis and hypersensitivity pneumonitis, are now available to manage interstitial lung disease progression, while oxygen therapy and pulmonary rehabilitation remain crucial for advanced cases. 

Chronic ILD cases, particularly IPF, are increasing globally, largely driven by aging populations and environmental factors. This expanding patient population creates a continual need for effective long-term treatments, thereby supporting market growth. Innovations in imaging and diagnostic tools are enabling clinicians to identify ILD subtypes earlier, thereby enhancing treatment outcomes and supporting demand for targeted therapies. In addition, pharmaceutical companies are investing in the development of new ILD therapies, with regulatory bodies prioritizing chronic respiratory disease treatments.

However, factors continue to have an impact on market growth potential. High treatment costs, limited treatment efficacy across diverse ILD types, and diagnostic complexity are some major challenges. Antifibrotic drugs like nintedanib and pirfenidone are costly, limiting access in low-income markets. Side effects also deter adherence, while complex diagnosis processes delay treatment initiation.

Some Key Takeaways:

• North America Interstitial Lung Disease (ILD) treatment market led in terms of revenue contribution to the global market in 2023. 
• The US is a major revenue contributor, driven by high prevalence rates of ILDs, advanced healthcare infrastructure, and significant investment in pharmaceutical R&D.
• In Europe, Germany and France are key markets, driven by robust healthcare systems and increasing awareness of ILDs.
• The Asia Pacific is expected to register fastest revenue growth rate over the forecast period. 
• Presence of major companies in Japan such as Shionogi and Nippon Shinyaku, which are expanding their ILD treatment portfolios, are also key factors supporting APAC market growth.
• The Idiopathic Pulmonary Fibrosis (IPF) segment is expected to register fastest revenue growth rate and account for largest revenue share among the disease type segments in the ILD treatment market over the forecast period.
• The CT scan segment is expected to account for largest revenue share among the diagnosis segments over the forecast period.
• The antifibrotics segment is expected to account for largest revenue share among the treatment segments over the forecast period.
• The tablet segment among the form segments is projected to dominate in terms of revenue share as this form is widely preferred owing to easy and convenient administration route.
• The oral segment is expected to maintain a lead in terms of revenue share among the route of administration segments over the forecast period.
• The hospital pharmacies segment is expected to continue to account for largest revenue share among the distribution segments over the forecast period.
• The hospitals segment among the end-user segments is expected to continue to maintain dominance in terms of revenue share over the forecast period. 
• The competitive landscape in the global Interstitial Lung Disease (ILD) treatment market is characterized by intense rivalry among major pharmaceutical companies. 
• Boehringer Ingelheim, Roche, Sanofi, and Novartis are major companies in the market, with key focus on expanding portfolios, especially in the antifibrotic and anti-inflammatory drug segments.

Company List:

• Boehringer Ingelheim
• Hoffmann-La Roche (Roche)
• GlaxoSmithKline (GSK)
• Bayer
• Novartis
• Sanofi
• Johnson & Johnson (Janssen)
• AstraZeneca
• Bellerophon Therapeutics
• Philips
• Siemens Healthineers
• Merck
• Theravance Biopharma
• GE Healthcare
• Fujirebio (Miraca) 

Recent Developments:

• October 17, 2024: Boston University’s Center for Regenerative Medicine (CReM) and Boston Medical Center (BMC) announced a new partnership with global biopharma leader, GlaxoSmithKline (GSK), to advance research on innovative models for studying and treating lung diseases, including pulmonary fibrosis. This collaboration will leverage GSK’s resources and expertise to deepen the research team’s understanding of how defective lung epithelial cells, particularly alveolar type 2 (AT2) cells, contribute to disease onset and progression. The initiative aims to create a research platform that could significantly advance lung disease studies and improve drug development efforts, offering promising new pathways for treatment for those affected by these conditions.
• September 16, 2024: Boehringer Ingelheim announced that its FIBRONEER-IPF trial achieved its primary goal, demonstrating a significant difference in Forced Vital Capacity (FVC) [mL] change from baseline at 52 weeks compared to placebo. FVC is a key indicator of lung function. Following these promising results, Boehringer Ingelheim plans to submit a new drug application for nerandomilast to the U.S. Food and Drug Administration (FDA) and regulatory bodies globally. The FDA previously granted nerandomilast Breakthrough Therapy Designation for IPF in 2022. Nerandomilast, an oral investigational inhibitor of phosphodiesterase 4B (PDE4B), is not yet approved, and its safety and efficacy remain under investigation. This drug is being evaluated through the FIBRONEER global program, which includes two Phase III trials—FIBRONEER-IPF for idiopathic pulmonary fibrosis (IPF) patients and FIBRONEER-ILD for individuals with Progressive Pulmonary Fibrosis (PPF).

Global Interstitial Lung Disease Treatment Market Segmentation

By Disease Type:

• Interstitial Pneumonia
• Idiopathic Pulmonary Fibrosis
• Nonspecific Interstitial Pneumonitis
• Hypersensitivity Pneumonitis
• Cryptogenic Organizing Pneumonia
• Acute Interstitial Pneumonitis
• Desquamative Interstitial Pneumonitis

By Diagnosis:

• Biopsy
• Bronchoscopy
• Lung Function Test
• Blood Test
• X-ray
• CT Scan
• Others

By Treatment:

• Antibiotics
• Corticosteroids
• Lung Transplant
• Cytotoxic Drugs
• Antifibrotics
• Pulmonary Rehabilitation
• Oxygen Therapy
• Others

By Dosage Form:

• Tablet
• Injection
• Others

By Route of Administration:

• Oral
• Intravenous
• Others

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By End-Users:

• Clinics
• Hospitals
• Others
•  
  • United States

Regional Segmentation: 

North America

• Canada
• Mexico

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Rest of Latin America 

Middle East & Africa

• Saudi Arabia
• South Africa
• United Arab Emirates
• Israel
• Rest of MEA